Correlation Between Biomarin Pharmaceutical and Akero Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Biomarin Pharmaceutical and Akero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biomarin Pharmaceutical and Akero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biomarin Pharmaceutical and Akero Therapeutics, you can compare the effects of market volatilities on Biomarin Pharmaceutical and Akero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biomarin Pharmaceutical with a short position of Akero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biomarin Pharmaceutical and Akero Therapeutics.

Diversification Opportunities for Biomarin Pharmaceutical and Akero Therapeutics

-0.69
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Biomarin and Akero is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Biomarin Pharmaceutical and Akero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Akero Therapeutics and Biomarin Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biomarin Pharmaceutical are associated (or correlated) with Akero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Akero Therapeutics has no effect on the direction of Biomarin Pharmaceutical i.e., Biomarin Pharmaceutical and Akero Therapeutics go up and down completely randomly.

Pair Corralation between Biomarin Pharmaceutical and Akero Therapeutics

Given the investment horizon of 90 days Biomarin Pharmaceutical is expected to under-perform the Akero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Biomarin Pharmaceutical is 1.19 times less risky than Akero Therapeutics. The stock trades about -0.19 of its potential returns per unit of risk. The Akero Therapeutics is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  2,599  in Akero Therapeutics on August 31, 2024 and sell it today you would earn a total of  618.00  from holding Akero Therapeutics or generate 23.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Biomarin Pharmaceutical  vs.  Akero Therapeutics

 Performance 
       Timeline  
Biomarin Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Biomarin Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Akero Therapeutics 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Akero Therapeutics are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Akero Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Biomarin Pharmaceutical and Akero Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Biomarin Pharmaceutical and Akero Therapeutics

The main advantage of trading using opposite Biomarin Pharmaceutical and Akero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biomarin Pharmaceutical position performs unexpectedly, Akero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will offset losses from the drop in Akero Therapeutics' long position.
The idea behind Biomarin Pharmaceutical and Akero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bonds Directory
Find actively traded corporate debentures issued by US companies